Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
XOMA Royalty Corporation ( (XOMA) ) just unveiled an update.
On May 21, 2026, XOMA Royalty Corporation held its 2026 Annual Meeting of Stockholders, where shareholders approved amendments to the 2010 Long Term Incentive and Stock Award Plan, adding 425,000 shares and extending its term to March 16, 2036, and authorized a new 2026 Employee Stock Purchase Plan covering 500,000 shares. Stockholders also re-elected all director nominees, ratified Deloitte & Touche LLP as independent auditor, and backed executive compensation on an advisory basis, reinforcing management’s compensation framework and capital structure flexibility.
Effective May 21, 2026, in connection with a pending merger with Ligand Pharmaceuticals Incorporated, the board amended XOMA’s bylaws to address Nevada controlling interest statutes and adopt exclusive forum provisions designating Nevada state courts and U.S. federal courts for specified corporate and securities disputes. These bylaw changes, together with the equity plan approvals, are designed to support the merger process, clarify litigation venues, and enhance corporate governance stability for shareholders.
The most recent analyst rating on (XOMA) stock is a Hold with a $39.00 price target. To see the full list of analyst forecasts on XOMA Royalty Corporation stock, see the XOMA Stock Forecast page.
Spark’s Take on XOMA Stock
According to Spark, TipRanks’ AI Analyst, XOMA is a Neutral.
The score is driven primarily by improved recent profitability and free cash flow, tempered by balance-sheet leverage and historical/ongoing volatility. Technicals add support via a strong uptrend, while valuation is only moderate at ~20.9x earnings. Corporate events are a positive catalyst given the announced acquisition terms and potential CVR upside.
To see Spark’s full report on XOMA stock, click here.
More about XOMA Royalty Corporation
XOMA Royalty Corporation operates in the biopharmaceutical royalty and licensing sector, focusing on acquiring and managing royalty interests and related payment streams from pharmaceutical and biotechnology assets. The company’s model centers on monetizing clinical and commercial-stage therapies, positioning it as a specialized player in the life sciences finance and royalty aggregation market.
Average Trading Volume: 216,358
Technical Sentiment Signal: Buy
Current Market Cap: $526.5M
For an in-depth examination of XOMA stock, go to TipRanks’ Overview page.